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EXECUTIVE SUMMARY 
This report aims to provide a recommendation on whether to buy, sell, or hold stock in 
ANI Pharmaceuticals, Inc., a pharmaceutical company located in northern Minnesota. The 
recommendation is based on a complete financial analysis and valuation built from both 
qualitative information and quantitative data. 
At the end of this report, readers will have a better understanding of what goes into a 
financial analysis and valuation and be given a recommendation to buy ANI stock. 
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INTRODUCTION 
A firm’s financial valuation is based on both qualitative and quantitative information. 
This information may include, but is not limited to, industry characteristics, market analysis, firm 
characteristics, historical financial performance, and strategy. Financial analysts often assess this 
data with the intent of issuing common stock buy/hold/sell recommendations to clients.  
This report will focus on the financial analysis and valuation of ANI Pharmaceuticals, 
Inc. (Baudette, MN). I chose to analyze ANI Pharmaceuticals, Inc. because I thought it would be 
interesting to see how the current pandemic and economic crisis may impact a pharmaceutical 
company’s value. 
In order to fully analyze ANI Pharmaceuticals, Inc., its data will be compared to a 
competing firm – Assertio Therapeutics, Inc. (Lake Forest, IL). Both companies operate under 
Standard Industrial Classification Code (SIC) #2834 – Pharmaceutical Preparations. 
The report outlines key characteristics of the pharmaceutical industry before moving into 
a description of ANI Pharmaceuticals, Inc. It then examines several risks related to the company, 
as well as compares ANI data to Assertio. Finally, the report provides a thorough financial 
analysis and valuation projection as well as a recommendation for ANI stock. 
INDUSTRY CHARACTERISTICS 
 To be able to assess the historical performance of ANI and to project its future 
performance, it’s important to analyze the context of its operations, beginning with the firm’s 
industry. The pharmaceutical industry plays an important role in meeting society’s needs by 
providing effective medicines and drugs. The industry is a major source of medical innovation, 
as the primary focus of firms within the industry is to develop, produce, and market drugs or 
pharmaceuticals licensed for use as medications. Industry performance and profitability are often 
determined by two factors: industry effects and firm effects. Industry effects deal with the 
7 
 
underlying economic structure of the industry, while firm effects are attributable to the actions 
strategic leaders take. Conceptual frameworks such as the five-forces model and PESTEL are 
used to evaluate the performance and profitability of the pharmaceutical industry. 
Five-Force Model 
 The five-force model is a framework that identifies five key factors that are used to 
determine the profit potential of an industry. These factors include threat of entry, power of 
suppliers, power of buyers, threat of substitutes, and rivalry among existing firms. Based on the 
analysis, it’s clear that the pharmaceutical industry is not attractive to new entrants. 
Threat of Entry - low 
 The costs associated with research and development of new products and strict 
government regulations create high entry barriers for the pharmaceutical industry. The threat of 
entry posed by potential new competitors in the pharmaceutical industry is low because of the 
large economies of scale and high capital investments required of potential new companies. 
Power of Suppliers - low 
 Suppliers provide raw materials, components, intermediate products and other supplies. 
There are a number of suppliers willing to provide these materials; thus, suppliers have very little 
opportunity to bargain or attempt to influence market prices. Many suppliers are happy to supply 
big pharmaceutical companies because of the benefits created by being associated with industry 
leaders. 
Power of Buyers - medium 
 Patents for new products last for 20 years, which allows the manufacturer to dictate the 
prices during that time. However, once generic production begins and prices become more 
competitive, the power shifts to the buyers. Buyers in the pharmaceutical industry include 
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hospitals and other health care organizations that often buy in bulk quantities. This exerts 
pressure on pharmaceutical companies to keep prices in check, which gives bulk buyers more 
bargaining power. Regular customers, however, have lost bargaining power due to price 
increases and competition among branded and generic drugs. 
Threat of Substitutes – high 
 If the product is still in its patent period, there are no substitutes for that product. Once 
the patent period expires, generic production begins, and substitutes are developed. There is also 
the threat of alternative medicine and treatments. The more threats of substitution there are, the 
less attractive the pharmaceutical industry will be. 
Rivalry Among Existing Firms - high 
 The pharmaceutical industry is one of the most competitive industries in the world, with 
many well-established players. There are a large number of small and large companies, and a 
recent trend of mergers and acquisitions has large industries absorbing the smaller companies, 
creating increased rivalry among the top firms. Technology and innovation create an increased 
level of rivalry as firms within the industry compete to dominate new technologies. 
PESTEL Framework 
 While the five-force model looks at forces at work within an industry, the PESTEL 
framework focuses on analyzing the external factors that might affect the industry; these factors 
include: political, economic, sociocultural, technological, ecological, and legal factors. Applying 
the PESTEL framework to the pharmaceutical industry can give a clear understanding of what 
external factors might impinge upon a firm within the industry. 
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Political 
 As commercial interests of the pharmaceutical industry and the public health coincide, 
the government has developed systems to regulate the industry. As a result, the government has 
become a major political player keen on shaping the standards and processes that define 
regulations against unethical promotion and excessive industry profits by setting effective length 
of a drug’s patent life. There is also heavy regulation associated with the research and 
development process for approval of new drugs, which is often lengthy and expensive. 
Economic 
 The pharmaceutical industry, along with the healthcare industry, greatly align with Gross 
Domestic Product (GDP) growth. There is an unlimited demand for health care that’s often met 
with a limited supply of resources such as funding. 
Social 
 The growth of global pharmaceutical markets is stimulated by population growth, as well 
as an aging population. As population growth is outpaced by GDP growth, the increase in middle 
class income to spend on consumer health products can lead to increased revenue of the industry. 
Sales and revenues also increase as pharmaceutical companies take advantage of changes in 
social life, accompanied by higher incidences of chronic diseases, which drive demand for 
innovative therapies such as vitamins and supplements.  
Technological 
 Technology and pharmaceutical innovation are heavily related. Advancements in 
technology often lead to the discovery of newer, more effective drugs and therapies. 
Technological advancements also keep companies within the industry highly competitive as 
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companies have no option other than to adopt new technologies. This leads to a constant pressure 
to innovate. 
Environmental 
 Like many industries, as the pharmaceutical industry expands, it faces serious 
environmental problems that arise from increased global production. However, the 
pharmaceutical industry commits itself to using environmental management systems (EMSs) 
through integration between their environmental, health and safety practices with principles of 
quality-based management and carbon offset. Overall, the environmental impact of the 
pharmaceutical industry compared to other industries (energy, automotive, aviation, chemical) is 
relatively low, with much higher returns to society from research and development. 
Legal 
 Government regulations are extremely important in the pharmaceutical industry because 
they help bridge the gap between public and private interests. The pharmaceutical industry is 
highly regulated by multiple U.S. and Canadian government agencies, such as the FDA, the 
DEA, the Centers for Medicare and Medicaid Services (CMS), and Health Canada. The 
pharmaceutical industry is subject to extensive and complex rules and regulations, which are 
subject to revision from time to time, and although many companies have experience with these 
regulations, there can be no assurance that a company will be able to fully comply with all 
applicable regulations. Heavy regulations make research and development an expensive and 
time-consuming process for new product approval. 
COMPANY DESCRIPTION  
ANI Pharmaceuticals, Inc. is an integrated specialty pharmaceutical company that 
develops, manufactures, and markets high quality branded and generic prescription 
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pharmaceuticals. ANI’s primary focus is on niche and high barrier to entry opportunities 
including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex 
formulations. 
ANI was incorporated in Canada in August of 1996 but was reincorporated as a Delaware 
corporation in June of 2001. The company was originally based in Baltimore, Maryland, with a 
manufacturing facility in Gulfport, Mississippi. While still privately held, ANI acquired 
manufacturing plants in Baudette, Minnesota. In 2009, Arthur Przybyl, a veteran of the 
pharmaceutical industry, became President and CEO, and in 2010, he decided to shut down the 
Baltimore office and relocated ANI headquarters to Baudette. ANI currently has three 
pharmaceutical manufacturing facilities, two of which are located in Baudette, Minnesota and 
one located in Oakville, Ontario. Together they are capable of producing oral solid dose products 
as well as semi-solids, liquids and topicals, controlled substances, and potent products that must 
be manufactured in a fully contained environment. ANI also performs contract manufacturing for 
other pharmaceutical companies. 
In June of 2013, pursuant of a merger agreement dated April 2013, ANI became a wholly 
owned subsidiary of BioSante Pharmaceuticals, Inc. in an all-stock, tax-free reorganization 
(merger). The merger was accounted for as a reverse acquisition, which means that ANI was 
considered the acquiring entity for accounting purposes. Since the merger, ANI has been 
operating under the leadership of the ANI management team and ANI’s historical financial data 
has replaced BioSante’s historical financial data for all periods prior to the merger. For all 
periods after the completion of the merger, the financial data of both companies are included in 
the consolidated financial statements. 
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In March of 2014, ANI completed a follow-on (secondary) public offering of common 
stock, and in December of 2014, ANI issued $143.8 million of their convertible senior notes in a 
registered public offering. In December of 2017, ANI entered a five-year senior secured credit 
facility with Citizens Bank. The credit agreement was comprised of a $75 million five-year 
secured term loan and a $50 million senior secured revolving credit facility. In December of 
2018, ANI refinanced their $125 million credit agreement by entering into an amended and 
restated senior secured credit facility. 
ANI used the additional funds resulting from the public and convertible debt offerings 
and from the credit agreement to acquire Abbreviate New Drug Applications, New Drug 
Applications, and product rights. They also entered into agreements to obtain the distribution 
rights for various products. As a result of those acquisitions and distribution agreements, ANI 
was able to launch three products in 2014, six products in 2015, 11 products in 2016, six 
products in 2017, and 11 products in 2018, bringing their portfolio of products to 42 as of 
December 31, 2018. ANI continues to focus on the re-commercialization of these products while 
increasing their portfolio of generic and mature brand products. 
In August of 2018, ANI subsidiary – ANI Pharmaceuticals Canada Inc., acquired all the 
issued and outstanding equity interest of WellSpring Pharma Services Inc., a Canadian company 
that performed contract development and manufacturing of pharmaceutical products.  
 The main objective of ANI Pharmaceuticals, Inc. is to create long term shareholder value 
by building a sustainable and growing base business in generic and mature brand pharmaceutical 
products. 
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Management and Corporate Governance 
 ANI operates under the guidance of a management team, as well as a separate board of 
directors, who sit on the following board committees: the audit and finance committee, the 
nominating and corporate governance committee, and the compensation committee. 
ANI’s management team includes several highly experienced individuals, including 
President and CEO, Arthur S. Przybyl, who brings over 25 years of experience to ANI. Prior to 
joining ANI in March of 2009, Mr. Przybyl was the President and CEO of Akorn, Inc., a 
NASDAQ specialty pharmaceutical company that manufactures and markets ophthalmic, liquid 
and lyophilized injectable, and vaccine drug products. He’s also held leadership roles at Hearing 
Innovations, Inc. and Bioject, Inc., both medical device companies. 
The management team at ANI includes the following individuals: 
Table 1. List of Executives 
Executive Position Salary 
Arthur S. Przybyl President and Chief 
Executive Officer 
$4,197,933 
Stephen P. Carey Vice President and Chief 
Financial Officer 
$1,438,750 
James G. Marken Sr. Vice President, 
Operations and Product 
Development 
$1,009,589 
Robert Schrepfer Sr. Vice President, Business 
Development and Specialty 
Sales 
$1,444,156 
Dr. David Sullivan Vice President, Quality 
Operations 
N/A 
Dr. Mark J. Ginski Vice President, Corticotropin 
Product Development 
N/A 
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The Board of Directors includes the following individuals: 
Table 2. List of Board of Directors 
Executive Position Committee(s) 
Robert E. Brown, Jr. Chairman of the Board Nominating and Corporate 
Governance - Chair 
Thomas J. Haughey Director Audit and Finance – Chair, 
Compensation – Member 
David B. Nash Director Audit and Finance – Member, 
Nominating and Corporate 
Governance – Member 
Thomas A. Penn Director Compensation – Chair, 
Nominating and Corporate 
Governance – Member 
Patrick D. Walsh Director Audit and Finance – Member, 
Compensation - Member 
Arthur S. Przybyl Director N/A 
 
RISK ANALYSIS 
 There are several risks that ANI Pharmaceuticals, Inc. faces in their day to day 
operations. These risks can be divided into four major categories: industry risks, business risks, 
risks related to accounting, tax, and SEC rules and regulations, and risks related to debt. 
Industry 
 Consolidation throughout the pharmaceutical industry has significantly increased in 
recent years, particularly in distribution channels and among generic and brand drug companies. 
As consolidation throughout the wholesale distributor network for pharmaceutical products 
increases, there is an increased concentration of wholesale customers. The number of retail 
market chains and independent drug stores and small chains has also decreased as retail 
consolidation occurs, which increases the concentration of retail customers. As the consolidation 
trend continues, there will be a much smaller number of companies who each control a large 
share of pharmaceutical distribution channels. 
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 In addition, consolidation among pharmaceutical companies has created opportunities by 
reducing the number of competitors, but as competitors grow larger through consolidation, so do 
their resources. This allows large competitors the ability to aggressively decrease prices to gain 
market share and more effectively market their products. 
 Other industry risks could include the following: significant additional costs due to 
complying with federal, state, and local laws and regulations; failure to comply with complex 
governmental obligations and regulatory requirements that may require subjective decisions; 
meeting the steadily increasing product quality standards; and healthcare reform legislation 
having material adverse effects on businesses, financial position, and operating results. 
Business 
Along with the industry risks previously discussed, ANI faces risks directly related to 
their business, many of which involve outside parties. ANI’s ability to manufacture and 
distribute products depends on a limited number of suppliers and changes in these suppliers must 
usually be approved through a Prior Approval Supplement (PAS) by the FDA. ANI has acquired 
several products that cannot be manufactured in their facilities, so they must be able to secure 
and maintain qualified contract manufacturers for those products. ANI also relies on third parties 
to assist with clinical studies; if the third parties do not perform as required or expected, clinical 
studies may need to be extended, delayed, terminated, or repeated – all of which are costly and 
time consuming. 
 Other risks associated with ANI include competition from other pharmaceutical 
manufacturers that threaten commercial acceptance and product pricing; the inability to protect 
intellectual property in the U.S. and foreign countries that could negatively affect sales of 
branded products; expectations to spend a significant amount of resources on research and 
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development efforts, which may not result in marketable products; production at any or all of 
ANI facilities being interrupted; limited staffing also poses a risk as ANI is dependent upon a 
few key players (competition for talent is intense, especially in northern Minnesota); and finally, 
ANI relies significantly on information technology, so any failure, inadequacy, interruption, or 
security lapse of that technology could negatively affect the business. 
Accounting, Tax, and SEC Rules and Regulations 
 ANI risks associated with accounting, tax, and SEC rules and regulations include the 
following: increased exposure to tax liabilities (including foreign tax liabilities); use of a variety 
of estimates, judgements, and assumptions in preparing consolidated financial statements; 
changes in estimates regarding the fair value of goodwill or intangible assets; policies regarding 
returns, allowances and charge books, and marketing programs; and finally, management 
compliance with public company regulations. 
Debt 
 ANI risks associated with debt include the following: making interest and principal 
payments on notes, which requires a significant amount of cash; conditional conversion features 
on the notes, which if triggered will allow note holders the ability to convert their notes; and 
finally, accounting for the notes. When ANI accounts for their notes payable, they recognize it as 
a non-cash interest expense, which has and will continue to reduce net income and earnings per 
share. 
SIGNIFICANT ACCOUNTING POLICIES 
 Many of ANI’s significant accounting policies involve the recognition of revenue. From 
2014 to 2018, the Financial Accounting Standards Board (FASB) has made significant changes 
to how a company should recognize revenue. In May 2014, FASB issued guidance for revenue 
17 
 
recognition for contracts, superseding the previous revenue recognition requirements, along with 
most existing industry-specific guidance. The guidance requires an entity to review contracts in 
five steps: 1) identify the contract, 2) identify performance obligations, 3) determine the 
transaction price, 4) allocate the transaction price, and 5) recognize revenue. The new standard 
resulted in enhanced disclosures regarding the nature, amount, timing, and uncertainty of 
revenue arising from contracts with customers. In August 2015, FASB issued guidance 
approving a one-year deferral, making the standard effective for reporting periods beginning 
after December 15, 2017. In March 2016, FASB issued guidance to clarify the implementation 
guidance on principal versus agent considerations for reporting revenue gross rather than net, 
with the same deferred effective date. In April 2016, FASB issued guidance to clarify the 
implementation guidance on identifying performance obligations and the accounting for licenses 
of intellectual property. In May 2016, FASB issued guidance rescinding SEC paragraphs related 
to revenue recognition; at this time, they also issued guidance to clarify the implementation 
guidance on assessing collectability, presentation of sales tax, noncash consideration, and 
contracts and contract modifications as transition. 
 In response to these changes, ANI performed a comprehensive review of existing revenue 
arrangements as of January 1, 2018 following the five-step model. Analysts indicated that there 
were no significant changes to how the amount and timing of revenue is recognized under the 
new guidance. Additionally, analysts indicated that there were no significant changes to how 
costs to obtain and fulfill customer contracts are recognized under the new guidance. The 
adoption of this guidance did not have a material impact on the consolidated financial 
statements. It did however impact the way ANI analyzes, documents, and discloses revenue 
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recognition under customer contracts, which resulted in additional disclosures in their financial 
statements. 
STOCK PRICE PERFORMANCE 
Figure 1. ANI Stock Price History 
The stock price for ANI closed at USD 38.34 on April 2, 2020. The stock price has seen 
some significant changes over the past 5 years, reaching a maximum price of USD 84.33 on July 
22, 2019. Since then, ANI stock price has decreased to 38.34 as of April 2, 2020, with a 
significant drop between February 3, 2020 and March 9, 2020. When comparing beginning price 
to year end price, ANI stock suffered a 30.15% loss in 2018, but saw growth in 2019 of 36.98%. 
The most recent drop in ANI stock price is largely due to the current global pandemic 
that has had a significant impact on the U.S. stock market. As we begin to navigate our way 
through the situation and figure out a solution, I expect to see the price of ANI stock rise. 
According to the article, “Has ANI Pharmaceuticals (ANIP) Outpaced Other Medical 
Stocks This Year?” ANI ranks #1 in the Zacks Rank system, a system that emphasizes earnings 
estimates and estimate revisions to find stocks with improving earnings outlooks based on year-
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to-date performance. The system has a long record of success, and these stocks tend to be on 
track to beat the market over the next one to three months. 
SHAREHOLDER ANALYSIS 
 As of December 31, 2019, there were 250 institutional shareholders holding 10,123,250 
shares of ANI stock, which represents roughly 68.20% of total shares. An institutional 
shareholder is a business, such as a mutual fund, that holds shares in publicly traded companies. 
They are important to placing new issues of stocks because they can often afford to buy more of 
an issue than individual investors. They are also typically powerful and have relatively high 
negotiating power against firm management, which means that they often have better and more 
access to accounting and financial information than the average individual investor. Based on the 
table below, the top five institutional shareholders account for roughly 32.95% of the total shares 
held by institutions. With BlackRock Inc., the largest institutional shareholder, accounting for 
roughly 15.29% of total shares. 
Table 3. Top Five Institutional Shareholders 
Institution Name Shares Held % of Total Institutional Shares 
BLACKROCK INC 1,547,749 15.29% 
VANGUARD GROUP INC 576,230 5.69% 
DIMENSIONAL FUND 
ADVISORS INC 
520,871 5.15% 
INVESCO LTD 364,390 3.60% 
MANGROVE PARTNERS 326,778 3.23% 
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PEER ANALYSIS 
 Assertio Therapeutics, Inc. is a specialty pharmaceutical company headquartered in Lake 
Forest, IL. Assertio is focused on providing neurology, orphan and specialty medicines, and their 
business strategy is based on three pillars: maintain, grow, and build. They operate under the 
same SIC code (pharmaceutical preparations) as ANI and are one of ANI’s main competitor in 
the Midwest region. 
 Assertio was formerly known as Depomed, Inc, and was originally incorporated in 
California in August of 1995. The company reincorporated in Deleware in August of 2018 and 
changed their name from Depomed to Assertio Therapeutics.  
 Although Assertio is much smaller than ANI in terms of Market Cap (ANI has a market 
cap of USD 468 million, while Assertio has a market cap of USD 52 million), they are both 
strong competitors in the Midwest region. 
Table 4. Overview Comparison of ANI and Assertio 
Company Ticker 
Symbol 
Revenues 
USD 
Market 
Cap USD 
PE Ratio ROA ROE 
ANI ANIP 206.5M 468.6M 77.48 3.68 8.33 
Assertio ASRT 229.5M 52.6M N/A 3.74 18.93 
 
HISTORICAL FINANCIAL ANALYSIS 
 To better understand how ANI is performing in comparison to Assertio, this report will 
compare various profitability, liquidity, financial leverage, and productivity ratios between the 
two companies calculated based on the financial statements for the years 2014-2018. ANI’s 
financial statements are audited by EisnerAmper LLP, who has served as the company’s auditor 
since 2013.  
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Profitability Ratios 
Table 5. Profitability Ratios 
Ratio 2018 2017 2016 2015 2014 
ANI: ROA % 3.68 (0.29) 1.29 5.6 18.65 
Assertio: ROA % 3.74 (9.05) (6.84) (7.3) 21.61 
ANI: ROE % 8.33 (0.62) 2.38 10.25 31.81 
Assertio: ROE % 18.93 (48.77) (31.27) (22.29) 52.51 
ANI: ROI % 9.35 8.5 7.1 12.48 13.72 
Assertio: ROI % 5.52 (4.78) 2.34 (9.36) 64.73 
ANI: EBITDA Margin % 18.31 16.73 16.25 43.82 37.1 
Asserito: EBITDA Margin % 68.04 19.36 28.09 10.31 63.73 
ANI: Gross Profit Margin % 63.77% 55.31% 62.07% 83.37% 79.50% 
Assertio: Gross Profit Margin % 85.78% 80.89% 80.79% 80.13% 86.74% 
 
 Profitability is best evaluated through ratios such as profit margin and return on assets. 
Return on equity, return on investments, and EBITDA margin are also good indicators of a 
company’s profitability. In terms of profitability, it’s difficult to say which company 
outperformed the other. Overall, ANI has had better returns than Assertio when comparing the 
companies return on assets (ROA), return on equity (ROE), and return on investments (ROI). 
Although ANI’s returns have declined throughout the past five years, with significant decreases 
from 2014 to 2015, they seem to be back on the right track showing increases in all three areas 
from 2017 to 2018. When comparing the companies EBITDA margins, Assertio, with the 
exception of 2015, has had much higher profits in terms of a percentage of revenues. Assertio 
has also consistently shown higher gross profit margins, with the exception of 2015.  
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Liquidity Ratios 
Table 6. Liquidity Ratios 
Ratio 2018 2017 2016 2015 2014 
ANI: Current Ratio .92 3.35 3.22 16.38 15.38 
Assertio: Current Ratio .85 .74 1.35 1.41 10.74 
ANI: Quick Ratio .61 2.1 2.05 14.37 13.5 
Assertio: Quick Ratio .57 .64 1.23 1.28 10.2 
 
Liquidity measures the ability to pay short term obligations; it can be measured through 
ratios such as the current ratio and the quick ratio. The current ratio of ANI has dropped 
significantly throughout the past five years, falling below 1 in 2018. This shows that their current 
liabilities have been growing at a much higher rate than their current assets, and those liabilities 
currently outweigh the current assets. Assertio’s current ratio has also decreased throughout the 
years and fell below 1 in 2017. Both companies show similar trends when looking at quick ratio. 
While the current ratio is the proportion of the amount of current assets divided by the amount of 
current liabilities, the quick ratio only accounts for only the most liquid current assets. Overall, 
ANI seems to be slightly more liquid than Assertio.  
Financial Leverage Ratios 
Table 7. Financial Leverage Ratios 
Ratio 2018 2017 2016 2015 2014 
ANI: LT Debt to Equity .34 1.13 .71 .71 .79 
Assertio: LT Debt to Equity 2.02 3.21 2.87 2.56 .63 
ANI: Total Debt to Equity .93 1.15 .71 .71 .79 
Assertio: Total Debt to Equity 2.57 3.7 2.87 2.56 .63 
ANI: Interest Coverage 2.4 2.35 1.77 2.97 25.42 
Assertio: Interest Coverage .65 N/A .29 N/A 9.99 
 
 Financial leverage ratios are used to measure the value of equity in a company by 
analyzing its overall debt picture. While looking at the total debt to equity ratio between the two 
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companies, both ANI and Assertio show moderate numbers (.93 and 2.57 in 2018). This 
indicates low levels of risk for both companies. The debt to equity ratio also shows that ANI 
finances more assets through equity, while Assertio finances more assets through debt. The 
interest coverage ratio shows how efficiently a company can cover its interest payments with its 
available earnings. Based on the past five years, ANI is much more efficient at covering their 
interest payments as their interest coverage ratio is consistently higher than that of Assertio. 
 As ANI’s notes payable reach maturity, they are slowly shifting from long term debt to 
short term debt, while Assertio has begun to finance with more long term debt. 
Productivity Ratios 
Table 8. Productivity Ratios 
Ratio 2018 2017 2016 2015 2014 
ANI: Total Asset Turnover .48 .48 .42 .28 .36 
Assertio: Total Asset Turnover .32 .34 .35 .33 .64 
ANI: Receivables Turnover 3.26 3.38 3.78 3.89 3.76 
Assertio: Receivables Turnover 5.71 4.38 5.25 6.99 20.3 
ANI: Inventory Turnover 1.87 2.47 2.47 1.21 2.08 
Assertio: Inventory Turnover 2.25 5.57 7.43 7.17 1.63 
 
 Productivity ratios are important in evaluating the efficiency and effectiveness of a 
company. A few major indicators of a company’s productivity are turnover ratios such as total 
asset turnover, receivables turnover, and inventory turnover. Based on the ratios in the table 
above, ANI has consistently had a better total asset turnover, which shows that they have been 
better at using their assets to create sales. ANI has lower receivables and inventory turnover 
ratios, which means that they collect cash and sell inventory at a slower rate than Assertio. 
Overall, while ANI has been more productive in terms of creating sales from assets, Assertio has 
been more efficient in collecting cash and selling inventory. 
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PROSPECTIVE FINANCIAL ANALYSIS 
 Over the next five years, I expect to see ANI grow. I projected sales growth to be 14% in 
2019 (based on the most recent year’s growth rate), decreasing steadily until it grows at a rate of 
about 3% perpetually, which is slightly higher than the projected industry average of 2.5%. I 
chose to project ANI’s sales growth higher than the industry average because ANI has recently 
launched new products and received approval for commercialization of another product. ANI 
also has a trend of exceeding estimates and surpassing the market.  
 I projected cost of goods sold (COGS) as a percentage of sales to be 36.2% in 2019, 
decreasing steadily until it reaches 25% by 2023. Over the years, ANI has reduced the number of 
suppliers they use. As they begin purchasing a majority of their supplies in bulk from one or two 
main suppliers, they will end up decreasing their COGS. 
 I decided to keep all the operating capital ratios constant with the most recent year 
because as of 12/31/2018, ANI did not have any plans for capital projects that might alter the 
ratios. 
The Capital Asset Pricing Model (CAPM) describes the relationship between systematic 
risk and expected return on assets, particularly stocks. It can be very useful for firm valuation. I 
used the CAPM to determine the cost of equity used in calculating my weighted average cost of 
capital (WACC). I estimated the WACC to be 15.91%. The factors involved in the projection 
were a target percent financed with long term debt of 15%, a target percent financed with short 
term debt of 15%, a target percent financed with equity of 70%, a cost of equity of 20.82%, a 
cost of short term debt of 4.85%, a cost of long term debt of 7.03% (calculated by adding the BB 
bond spread rate of 2.18% to the risk free rate of 4.85%), and a tax rate of 21%. My cost of 
equity was calculated using a beta of 1.61, a risk-free rate of 4.85%, and a market risk premium 
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of 9.92%. The beta used in my calculation is the 5y monthly beta found on Yahoo Finance. The 
risk-free rate and the market risk premium I used were found on the Business Valuation 
Resources (BVR) Cost of Capital Professional platform of the American Society of Appraisers. 
The risk-free rate represents the 10-year treasury bond average annual rate, which covers the 
time spread of my valuation, and the market risk premium is the S&P 500 average annual return 
from 1928-2019. 
VALUATION 
 I used the valuation model based on discounting expected free cash flows at the weighted 
average cost of capital. I obtained relevant financial statement information from Mergent online 
for the years 2014-2018. 
 The forecasted stock price for ANI on March 31, 2020 is USD 41.17 per share. This 
forecasted price is higher than what the stock closed at on that date, which was USD 40.77. 
Comparing my estimated stock price of USD 41.17 to the market close price of USD 40.77 
shows that the stock is slightly undervalued. However, it is a very minimal margin and will be 
considered relatively fair valued. 
 I have included a sensitivity analysis for ANI, which will help determine how dependent 
the stock price is to different input variables such as beta and sales growth rate. The sensitivity 
analysis illustrates how different betas and sales growth rates affect the projected stock price. 
Lower betas and higher sales growth rates lead to higher projected stock prices, while higher 
betas and lower sales growth rates lead to lower projected stock prices. The green highlighted 
values represent a buy decision for ANI stock because the stock price would be undervalued and 
expected to rise, the yellow highlighted values represent a hold decision, and the red highlighted 
values represent a sell decision because the stock would be overvalued and expected to fall. 
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Figure 2. Sensitivity Analysis 
 BETA 1 1.2 1.4 1.61 1.8 
SALES GROWTH 1% $55.76 $48.06 $41.95 $36.77 $32.91 
 2% $60.25 $51.50 $44.62 $38.84 $34.55 
 3% $65.40 $55.44 $47.66 $41.17 $36.41 
 4% $71.31 $59.93 $51.12 $43.83 $38.50 
 5% $78.11 $65.08 $55.07 $46.84 $40.88 
 
 The sensitivity analysis shows a hold on ANI stock, but the sensitivity analysis is solely 
based on how different sales growth rates and betas affect the projected stock price, and does not 
take into account any qualitative information surrounding ANI Pharmaceuticals, Inc.  
INVESTMENT DECISION 
Based on the above financial analysis, as well as the company and industry quality 
analysis done prior to the financial analysis and the current state of the economy, it’s clear that 
ANI Pharmaceuticals, Inc is a well-established and relatively strong performing company. They 
have also recently launched new products and have announced that they’ve received FDA 
approval for new drug applications. 
Although my valuation model shows that ANI stock is fair valued and my sensitivity 
analysis recommends holding, I recommend that investors buy ANI stock. I believe that they 
have great future earnings potential, especially after the release of new products, and as 
mentioned previously, in terms of the medical industry, ANI stock is expected to grow at a 
higher rate than its competitors.  
The impact on the stock market due to the current pandemic situation is also a major 
factor in the decision to buy. ANI stock was trading as high as USD 84.33 in June of 2019 and as 
high as USD 67.14 in February of 2020 before the stock market took a huge hit. I strongly 
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believe that investors should take advantage of the current conditions and buy ANI stock, as I 
expect to see considerable growth as the economy begins to recover. 
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APPENDIX A: HISTORICAL FINANCIAL STATEMENTS 
  
 
 
ANI Pharmaceuticals Inc (NMS: ANIP) 
    
      
Exchange rate used is that of the Year End reported date  
     
      
      
As Reported Annual Balance Sheet  
     
Report Date 12/31/2018 12/31/2017 12/31/2016 12/31/2015 12/31/2014 
Currency USD USD USD USD USD 
Audit Status Not 
Qualified 
Not 
Qualified 
Not 
Qualified 
Not 
Qualified 
Not 
Qualified 
Consolidated Yes Yes Yes Yes Yes 
Cash & cash equivalents 43008000 31144000 27365000 154684000 169037000 
Accounts receivable, gross 112547000 93474000 77430000 35518000 26005000 
Adjustments for chargebacks & other allowances 47705000 34686000 31535000 13586000 8708000 
Accounts receivable, net 64842000 58788000 45895000 21932000 17297000 
Raw materials 27671000 22139000 14138000 10192000 5056000 
Packaging materials 2563000 1527000 930000 998000 794000 
Work-in-progress 1210000 510000 477000 456000 411000 
Finished goods 10620000 13901000 10812000 1897000 1368000 
Product inventory 42064000 38077000 26357000 13543000 7629000 
Reserve for excess/obsolete inventories 1561000 350000 174000 156000 111000 
Inventories, net 40503000 37727000 26183000 13387000 7518000 
Prepaid income taxes - 1162000 - 1127000 - 
Deferred tax assets, net of valuation allowance - - - - 7643000 
Prepaid expenses - - - - - 
Prepaid expenses & other current assets 4524000 2784000 3564000 1453000 1983000 
Total current assets 152877000 131605000 103007000 192583000 203478000 
Land 4558000 160000 160000 87000 87000 
Buildings 10079000 3835000 3756000 3682000 3682000 
Machinery, furniture & equipment 26814000 12334000 8176000 5623000 4822000 
Construction in progress 5040000 10663000 4293000 2189000 426000 
Computer equipment - - - - - 
Office equipment - - - - - 
Laboratory & equipment - - - - - 
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Property & equipment, gross 46491000 26992000 16385000 11581000 9017000 
Accumulated depreciation & amortization - - - - - 
Less: accumulated depreciation 8401000 6589000 5387000 4450000 3794000 
Property & equipment, net 38090000 20403000 10998000 7131000 5223000 
Restricted cash 5021000 5006000 5002000 - - 
Deferred financing costs, net - - - - 3307000 
Deferred tax asset, net of valuation allowance 27964000 22667000 26227000 17316000 7796000 
Investments - - - - - 
Deposits - - - - - 
Intangible assets, net 201604000 229790000 175792000 66397000 42067000 
Goodwill 3580000 1838000 1838000 1838000 1838000 
Other long-term assets 1468000 829000 - - - 
Total assets 430604000 412138000 322864000 285265000 263709000 
Current component of long-term borrowing, net of deferred financing costs 3256000 - - - - 
Current portion of long-term borrowing, net of deferred financing costs - 3353000 - - - 
Accounts payable 8884000 3630000 3389000 2066000 2654000 
Accrued expenses & other current liabilities 1707000 1571000 927000 617000 1269000 
Accrued royalties 8456000 12164000 11956000 606000 - 
Accrued compensation - - - - - 
Accrued compensation & related expenses 3524000 2306000 1631000 1188000 1348000 
Current income taxes payable 5022000 - 2398000 - 4253000 
Accrued government rebates 8974000 7930000 5891000 4631000 2264000 
Other accrued expenses - - - - - 
Accrued expenses - - - - - 
Returned goods reserve 12552000 8274000 5756000 2648000 1445000 
Current portion of convertible senior notes - - - - - 
Convertible notes, net of discount & deferred financing costs 112463000 - - - - 
Deferred revenue 711000 - - - - 
Total current liabilities 165549000 39228000 31948000 11756000 13233000 
Long-term royalties - - 625000 - - 
Long-term borrowings on secured term loan 68578000 71250000 - - - 
Deferred financing costs -1282000 -1304000 - - - 
Long-term borrowing, net of deferred financing costs & current borrowing 
component 
67296000 69946000 - - - 
Convertible notes, net of discount & deferred financing costs - 128208000 120643000 113427000 110691000 
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Other long-term liabilities 496000 - - - - 
Total liabilities 233341000 237382000 153216000 125183000 123924000 
Class C special stock - - - - - 
Common stock 1000 1000 1000 1000 1000 
Total capital stock - - - - - 
Treasury stock 659000 259000 - - - 
Additional paid-in capital 186812000 179020000 172563000 164431000 159509000 
Retained earnings (accumulated deficit) 11488000 -4006000 -2916000 -4350000 -19725000 
Accumulated other comprehensive loss, net of tax -379000 - - - - 
Total stockholders' equity (deficit) 197263000 174756000 169648000 160082000 139785000 
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ANI Pharmaceuticals Inc (NMS: ANIP) 
    
      
Exchange rate used is that of the Year End reported date  
     
      
      
As Reported Annual Income Statement  
     
Report Date 12/31/2018 12/31/2017 12/31/2016 12/31/2015 12/31/2014 
Currency USD USD USD USD USD 
Audit Status Not 
Qualified 
Not 
Qualified 
Not 
Qualified 
Not 
Qualified 
Not 
Qualified 
Consolidated Yes Yes Yes Yes Yes 
Licensing revenue - - - - - 
Royalty revenue - - - - - 
Net revenue 201576000 176842000 128622000 76322000 55970000 
Total revenue - - - - - 
Cost of sales (excluding depreciation & amortization) 73024000 79032000 48780000 12692000 11473000 
Research & development expense 15388000 9070000 2906000 2874000 2678000 
General & administration expense - - - - - 
Selling, general & administrative 44063000 31580000 27829000 21156000 17935000 
Licensing expense - - - - - 
Depreciation & amortization expense 33742000 27928000 22343000 6900000 3878000 
Intangible asset impairment charge - 903000 6685000 - - 
Total expenses - - - - - 
Total operating expenses 166217000 148513000 108543000 43622000 35964000 
Operating income (loss) 35359000 28329000 20079000 32700000 20006000 
Convertible note fair value adjustment - - - - - 
Interest expense, net 14758000 12035000 11327000 11008000 787000 
Other income (expense), net -550000 55000 -74000 41000 160000 
Interest income - - - - - 
Income (loss) before provision (benefit) for income taxes 20051000 16349000 8678000 21733000 19379000 
Current income tax expense (benefit) - federal 7985000 13175000 11717000 7264000 4818000 
Current income tax expense (benefit) - state 1751000 690000 1321000 611000 273000 
Total current income tax expense (benefit) 9736000 13865000 13038000 7875000 5091000 
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Deferred income tax expense (benefit) - federal -4630000 4065000 -8387000 -1468000 2113000 
Deferred income tax expense (benefit) - state -556000 -556000 -658000 -409000 154000 
Deferred income tax provision (benefit) - foreign -214000 - - - - 
Total deferredincome tax expense (benefit) -5400000 3509000 -9045000 -1877000 2267000 
Change in valuation allowance 221000 51000 134000 - -16726000 
Excess tax benefit from stock-based compensation awards - - 617000 360000 - 
Provision (benefit) for income taxes 4557000 17425000 4744000 6358000 -9368000 
Net income (loss) from continuing operations - - - 15375000 28747000 
Gain on discontinued operation, net of provision (benefit) for 
income taxes 
- - - - - 
Net income (loss) 15494000 -1076000 3934000 15375000 28747000 
Net income allocated to restricted stock - - 21000 85000 - 
Net income (loss) from continuing operations allocated to 
common shares 
- -1076000 3913000 15290000 - 
Weighted average shares outstanding - basic 11677000 11547000 11445000 11370000 10941000 
Weighted average shares outstanding - diluted 11772000 11547000 11573000 11557000 11053000 
Year end shares outstanding 11862193 11661429 11599565 11509092 11398724 
Net income (loss) from continuing operations per share - basic - - - 1.34 2.61 
Net income (loss) from discontinued operations per share - basic - - - - - 
Net income (loss) per share - basic 1.31 -0.09 0.34 1.34 2.61 
Net income (loss) from continuing operations per share - diluted - - - 1.32 2.59 
Net income (loss) from discontinued operations per share - diluted - - - - - 
Net income (loss) per share - diluted 1.3 -0.09 0.34 1.32 2.59 
Number of full-time employees 299 173 143 108 92 
Total number of employees - - - - - 
Number of common stockholders 100 140 150 160 200 
Number of class C stockholders 6 6 6 6 6 
Number of beneficiary stockholders - - - - - 
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ANI Pharmaceuticals Inc (NMS: ANIP) 
  
      
Exchange rate used is that of the Year End reported date  
     
      
      
As Reported Annual Cash Flow  
     
Report Date 12/31/2018 12/31/2017 12/31/2016 12/31/2015 12/31/2014 
Currency USD USD USD USD USD 
Audit Status Not 
Qualified 
Not 
Qualified 
Not 
Qualified 
Not 
Qualified 
Not 
Qualified 
Consolidated Yes Yes Yes Yes Yes 
Net income (loss) 15494000 -1076000 3934000 15375000 28747000 
Stock based compensation 6782000 6090000 6067000 3856000 3423000 
Deferred taxes -5180000 3560000 -8911000 -1877000 -14459000 
Acquired in-process research & development 1335000 - - - - 
Depreciation & amortization 33742000 27928000 22343000 6900000 3878000 
Loss on disposal of property & equipment - - - 40000 - 
Non-cash interest relating to equity-linked securities & 
loan cost amortization 
- - 7281000 6831000 559000 
Non-cash interest relating to convertible notes & loan 
cost amortization 
8465000 7666000 - - - 
Loss on repurchase of convertible notes 468000 - - - - 
Non-cash compensation relating to business combination - - - - - 
Employee & director stock based compensation - - - - - 
Intangible asset impairment charge - 903000 6685000 - - 
Convertible note fair value adjustment - - - - - 
Prepaid expenses & other assets - - - - - 
Accounts receivable, net -4743000 -12893000 -23963000 -4635000 -4784000 
Inventories, net -379000 5356000 -1938000 -5869000 -3468000 
Prepaid expenses - - - - -558000 
Prepaid expenses & other current assets -1142000 -17000 -647000 -314000 - 
Accounts payable & accrued liabilities - - - - - 
Accounts payable 3466000 3000 1076000 -1027000 225000 
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Accrued compensation - - - - - 
Accrued royalties -3708000 -417000 6269000 - - 
Accrued compensation & related expenses - 675000 443000 -160000 575000 
Current income taxes, net 6184000 -3560000 3525000 -5380000 4233000 
Accrued government rebates 1044000 2039000 1260000 2367000 2011000 
Accrued expenses, returned goods reserve & deferred 
revenue 
- - - - - 
Accrued expenses, returned goods reserve & other 
liabilities 
- - - 1157000 1651000 
Returned goods reserve 4278000 2518000 3108000 - - 
Accrued expenses, accrued compensation, & other 968000 - - - - 
Accrued expenses & other current liabilities - 644000 940000 - - 
Net cash & cash equivalents used in continuing 
operations 
- - - 17264000 22033000 
Net cash used in discontinued operation - - - - - 
Net cash flows from operating activities 67074000 39419000 27472000 17264000 22033000 
Acquisiton of WellSpring Pharma Services Inc., net of 
cash acquired 
-16467000 - - - - 
Cash acquired in business combination - - - - - 
Changes in restricted cash - - -5002000 - - 
Release of restricted cash - - - - - 
Acquisition of product rights & other related assets - -97624000 -
144494000 
-30500000 -34634000 
Acquisition of product rights, IPR&D, & other related 
assets 
-5169000 - - - - 
Acquisition of property & equipment -5743000 -10369000 -4566000 -2183000 -1120000 
Purchase of investments - - - - - 
Purchase of fixed assets - - - - - 
Net cash flows from investing activities -27379000 -
107993000 
-
154062000 
-32683000 -35754000 
Payment of debt issuance & convertible debt repurchase 
costs 
-1572000 - - - - 
Net proceeds from equity offering - - - - 46680000 
Net proceeds from convertible debt offering - - - - 138243000 
Purchase of call option overlay, net - - - - -15623000 
Payment of debt issuance costs - -2737000 -294000 - - 
Borrowings under term loan agreement - 75000000 - - - 
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Payments on term loan agreement -2813000 - - - - 
Repayments under line of credit, net - - - - - 
Proceeds from stock option exercises 2978000 353000 1570000 819000 819000 
Proceeds from warrant exercise - - - - 750000 
Excess tax benefit from share-based compensation 
awards 
- - 617000 360000 784000 
Repurchase of common stock under the stock 
repurchase program 
- - -2500000 - - 
Repurchase of convertible notes -26125000 - - - - 
Unwinding of portion of call option overlay, net 375000 - - - - 
Treasury stock purchases for restricted stock vestings & 
forfeitures 
-659000 -259000 -122000 -113000 - 
Fractional share payment - - - - - 
Proceeds from common stock warrant excercises - - - - - 
Proceeds from issuance of common stock by registered 
direct offering 
- - - - - 
Net cash & cash equivalents (unsed in)/provided 
continuing operations 
- - - - - 
Net cash flows from financing activities -27816000 72357000 -729000 1066000 171653000 
Change in cash & cash equivalents 11879000 3783000 -
127319000 
-14353000 157932000 
Cash, cash equivalents, & restricted cash, beginning of 
period 
36150000 - - - - 
Cash, cash equivalents, & restricted cash, end of period 48029000 - - - - 
Reconciliation of cash, cash equivalents, & restricted 
cash, beginning of period: cash & cash equivalents 
- 27365000 - - - 
Reconciliation of cash, cash equivalents, & restricted 
cash, beginning of period: restricted cash 
- 5002000 - - - 
Cash & cash equivalents at beginning of period - 32367000 154684000 169037000 11105000 
Reconciliation of cash, cash equivalents, & restricted 
cash, end of period: cash & cash equivalents 
- 31144000 - - - 
Reconciliation of cash, cash equivalents, & restricted 
cash, end of period: restricted cash 
- 5006000 - - - 
Cash & cash equivalents at end of period - 36150000 27365000 154684000 169037000 
Cash paid for interest, net of amounts capitalized 6285000 3759000 4078000 4205000 - 
Cash paid for income taxes, net 6397000 17786000 9537000 13255000 147000 
Interest paid, including acquired accrued interest - - - - - 
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Assertio Therapeutics Inc (NMS: ASRT) 
    
      
Exchange rate used is that of the Year End reported date  
     
      
      
As Reported Annual Balance Sheet  
     
Report Date 12/31/2018 12/31/2017 12/31/2016 12/31/2015 12/31/2014 
Currency USD USD USD USD USD 
Audit Status Not 
Qualified 
Not 
Qualified 
Not 
Qualified 
Not 
Qualified 
Not 
Qualified 
Consolidated Yes Yes Yes Yes Yes 
Cash & cash equivalents 110949000 126884000 117709000 101084000 488668000 
Short-term investments - 1205000 59711000 108684000 70773000 
Product sales, net 23078000 - - - - 
Receivables from Collegium Pharmaceutical, Inc. (Collegium) 14011000 - - - - 
Other accounts receivable 122000 - - - - 
Accounts receivable, net - 71919000 102056000 71125000 27008000 
Accounts receivable, net 37211000 - - - - 
Receivables from collaborative partners - 563000 533000 562000 1070000 
Raw materials 1376000 3008000 2362000 2944000 2141000 
Work-in-process 732000 204000 869000 1211000 1348000 
Finished goods 1288000 9830000 9802000 6339000 4984000 
Less: allowance for obsolescence - - - - 17000 
Inventories 3396000 13042000 13033000 10494000 8456000 
Income taxes receivable - - - 6358000 4030000 
Deferred tax assets, net - - - - 9601000 
Prepaid & other current assets 56551000 17238000 13162000 10665000 8014000 
Total current assets 208107000 230851000 306204000 308972000 617620000 
Marketable securities, long-term - - - - 6961000 
Furniture & office equipment 2237000 5986000 5879000 4919000 4097000 
Machinery & equipment 11391000 10783000 10757000 8456000 - 
Laboratory equipment 351000 3335000 5129000 5129000 5156000 
Leasehold improvements 9858000 6841000 6841000 6840000 6045000 
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Construction in progress - - - - - 
Property & equipment, gross 23837000 26945000 28606000 25344000 15298000 
Less: accumulated depreciation - - - - - 
Less: accumulated depreciation & amortization 10773000 13921000 13080000 10550000 8243000 
Property & equipment, net 13064000 13024000 15526000 14794000 7055000 
Intangible assets, net 692099000 793873000 902149000 1008994000 72361000 
Deferred tax assets - - - 22995000 - 
Investments 11784000 - - - - 
Other long-term assets 7812000 869000 1458000 7677000 7068000 
Total assets 932866000 1038617000 1225337000 1363432000 711065000 
Accounts payable 6138000 14732000 14855000 12805000 - 
Accrued rebates, returns & discounts 75759000 135828000 131536000 121058000 - 
Accrued compensation 5475000 7345000 11730000 13196000 - 
Accrued royalties 2773000 17370000 21703000 20555000 - 
Accrued restructuring & one-time termination costs 1578000 9483000 - - - 
Other accrued liabilities 21535000 26298000 25965000 29180000 - 
Accrued liabilities 31361000 60496000 59398000 62931000 - 
Income taxes payable - 126000 59000 - - 
Current portion of senior notes 120000000 82500000 - - - 
Accounts payable - - - - 1278000 
Accrued compensation - - - - 7248000 
Accrued rebates & sales discounts - - - - 20695000 
Allowance for product returns - - - - 15015000 
Accrued contract sales organization fees - - - - - 
Inventory & other contract manufacturing accruals - - - - 360000 
Royalty payable to PDL BioPharma, Inc. - - - - - 
Other accrued liabilities - - - - 8090000 
Accounts payable & accrued liabilities - - - - 52686000 
Contingent consideration liability - 156000 4578000 3318000 - 
Interest payable 11645000 13220000 15924000 18672000 - 
Deferred license revenue - - - - - 
Liability related to the sale of future royalties & milestones - - - - - 
Other current liabilities 1133000 3522000 892000 848000 4813000 
Total current liabilities 246036000 310580000 227242000 219632000 57499000 
Deferred license revenue, non-current portion - - - - - 
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Contingent consideration liability 1038000 1457000 10247000 11653000 14252000 
Senior notes 158309000 274720000 466051000 563473000 - 
Convertible notes 287798000 269510000 252725000 243035000 - 
Liability related to the sale of future royalties & milestones, less 
current portion 
- - - - - 
Deferred tax liabilities, net, non-current - - - - 32589000 
Convertible debt - - - - 229891000 
Other long-term liabilities 19350000 12842000 18284000 10584000 12387000 
Total liabilities 712531000 - - - - 
Common stock 6000 313857000 291634000 264511000 239961000 
Additional paid-in capital 402934000 75164000 75917000 78622000 76809000 
Retained earnings (accumulated deficit) -
182600000 
-219508000 -116744000 -28024000 47714000 
Accumulated other comprehensive gain (loss), net of tax -5000 -5000 -19000 -54000 -37000 
Total shareholders' equity (deficit) 220335000 169508000 250788000 315055000 364447000 
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Assertio Therapeutics Inc (NMS: ASRT) 
    
      
Exchange rate used is that of the Year End reported 
date  
     
      
      
As Reported Annual Income Statement  
     
Report Date 12/31/2018 12/31/2017 12/31/2016 12/31/2015 12/31/2014 
Currency USD USD USD USD USD 
Audit Status Not 
Qualified 
Not 
Qualified 
Not 
Qualified 
Not 
Qualified 
Not 
Qualified 
Consolidated Yes Yes Yes Yes Yes 
Product sales revenues 129966000 379880000 455066000 341750000 114219000 
Commercialization agreement, net 155743000 - - - - 
Royalties & milestones 26061000 - - - - 
Royalties revenues - 844000 831000 985000 1821000 
License & other revenue - - - - 31515000 
Non-cash PDL royalty revenue - - - - 242808000 
Total revenues 311770000 380724000 455897000 342735000 390363000 
Cost of sales (excluding amortization of intangible 
assets) 
18476000 72598000 87414000 67898000 15146000 
Research & development expenses 8042000 13718000 32631000 17541000 7116000 
Acquired in-process research & development - 24900000 - 54900000 - 
Other selling, general & administrative expense - - - - 121126000 
Total selling, general & administrative expense - - - - - 
Selling, general & administrative expenses 119218000 195696000 204498000 199352000 - 
Amortization of intangible assets 101774000 102745000 106845000 83344000 10161000 
Restructuring charges 20601000 13247000 - - - 
Non-cash gain on settlement agreement - - - 29900000 - 
Total costs & expenses 268111000 422904000 431388000 393135000 153549000 
Income (loss) from operations 43659000 -42180000 24509000 -50400000 236814000 
Litigation settlement -62000000 - - - - 
Gain on divestiture of Lazanda - 17064000 - - - 
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Interest & other income 1197000 681000 485000 599000 215000 
Loss on prepayment of Senior Notes - -5938000 -5777000 - - 
Interest expense 68881000 73552000 83719000 73436000 9275000 
Non-cash interest expense on PDL liability - - - - 14646000 
Total other income (expenses) - -61745000 -89011000 -72837000 -23706000 
Net income (loss) before income taxes 37975000 -
103925000 
-64502000 -
123237000 
213108000 
Current federal income tax provision (benefit) 896000 384000 1087000 -1679000 -2853000 
Current state income tax provision (benefit) 171000 -1813000 140000 160000 11000 
Current foreign income tax provision - - - - - 
Total current income tax provision (benefit) 1067000 -1429000 1227000 -1519000 -2842000 
Deferred federal income tax provision (benefit) - - 16291000 -39459000 80293000 
Deferred state income tax provision (benefit) - - 6700000 -6521000 3895000 
Total deferred income tax provision (benefit) - - 22991000 -45980000 84188000 
Provision for (benefit from) income taxes 1067000 -1429000 24218000 -47499000 81346000 
Net income (loss) 36908000 -
102496000 
-88720000 -75738000 131762000 
Weighted average shares outstanding - basic 63794000 62702404 61296875 60116530 58292633 
Weighted average shares outstanding - diluted 64208000 62702404 61296875 60116530 66307364 
Year end shares outstanding 64185224 63400348 61966188 60787309 59293428 
Net income (loss) per share - basic 0.58 -1.63 -1.45 -1.26 2.26 
Net income (loss) per share - diluted 0.57 -1.63 -1.45 -1.26 2.05 
Number of full time employees 116 434 490 494 324 
Number of common stockholders 19 20 21 21 23 
Number of beneficiary stockholders - - 24830 24752 - 
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Assertio Therapeutics Inc (NMS: ASRT) 
    
      
Exchange rate used is that of the Year End reported date  
     
      
      
As Reported Annual Cash Flow  
     
Report Date 12/31/201
8 
12/31/2017 12/31/2016 12/31/2015 12/31/2014 
Currency USD USD USD USD USD 
Audit Status Not 
Qualified 
Not 
Qualified 
Not 
Qualified 
Not 
Qualified 
Not 
Qualified 
Consolidated Yes Yes Yes Yes Yes 
Net income (loss) 36908000 -
102496000 
-88720000 -75738000 131762000 
Non-cash interest expense on PDL liability - - - - 14646000 
Non-cash PDL royalty revenue - - - - -
242808000 
Depreciation & amortization 10642600
0 
105502000 109375000 85737000 12025000 
Accretion of debt discount & debt issuance costs 21877000 19415000 17673000 - - 
Loss on prepayment of Senior Notes - 5938000 5777000 - - 
Amortization of investments - - - 358000 288000 
Loss (gain) on bargain purchase - - - - - 
Provision for inventory obsolescence 598000 2673000 1179000 224000 - 
Loss (gain) on disposal of property & equipment 669000 -271000 - 38000 19000 
Stock-based compensation 12585000 13016000 17172000 14228000 8930000 
Change in fair value of contingent consideration & unfavorable 
contract 
- - -146000 -2625000 2791000 
Change in fair value of contingent consideration -391000 -8024000 - - - 
Accretion of debt discount - - - 15629000 4200000 
Deferred income taxes - - 20290000 -44166000 87378000 
Gain (loss) on divestiture of Lazanda - -17064000 - - - 
Cash paid for in-process research & development - - - 25000000 - 
Acquired in-process research & development - 24900000 - - - 
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Excess tax benefit from stock-based compensation - - -637000 -4625000 -3190000 
Other adjustments 1023000 240000 611000 - - 
Accounts receivable 35271000 30137000 -30931000 -44117000 -15453000 
Receivables from collaborative partners - -30000 29000 508000 10170000 
Inventories 9048000 -1873000 -3718000 9329000 1689000 
Prepaid & other assets -56136000 -5114000 -2464000 6085000 -2190000 
Income taxes receivable - - 6359000 -2332000 -4030000 
Accounts payable & other accrued liabilities -33610000 -6436000 5862000 53073000 15076000 
Accrued rebates, returns & discounts -60069000 4292000 10478000 85348000 - 
Interest payable -1576000 -2705000 -2747000 15992000 - 
Accrued compensation - - - 5946000 171000 
Income taxes payable -126000 67000 59000 - -61875000 
Deferred revenue - - - - -15516000 
Net cash flows from operating activities 72497000 62167000 65501000 143892000 -55917000 
Purchase of property & equipment -5507000 -666000 -2860000 -1715000 -599000 
Investment in convertible instrument -3000000 - - - - 
Acquisition of business - - - -
105001100
0 
- 
Acquisition of in-process research & development - - - -25000000 - 
Acquisition of patents - - - - - 
Proceeds from disposal of property & equipment 145000 280000 - - - 
Purchases of marketable securities - -8277000 -68818000 -116209000 -73754000 
Proceeds from sale of other assets 80000 - - - - 
Maturities of marketable securities - 66557000 115207000 84884000 27046000 
Sales of marketable securities 1200000 - 2007000 - - 
Net cash flows from investing activities -7082000 57894000 45536000 -
110805100
0 
-47307000 
Proceeds from issuance of convertible debt - - - - 345000000 
Convertible debt issuance costs - - - - -10775000 
Proceeds from issuance of senior notes - - - 562063000 - 
Payment of contingent consideration liability -184000 -1673000 - - - 
Senior notes issuance costs - - - -511000 - 
Repayment of senior notes -82500000 -
110000000 
-
100000000 
- - 
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Prepayment fees for repayment of senior notes - - -5000000 - - 
Fees for early repayment & modifications of Senior Notes - -7400000 - - - 
Proceeds from sale of future royalties & milestones to PDL 
BioPharma, Inc. 
- - - - - 
Proceeds from issuance of common stock 2020000 8940000 9951000 10398000 9803000 
Shares withheld for payment of employee's withholding tax liability -686000 -753000 - - - 
Excess tax benefit from stock-based compensation - - 637000 4625000 3190000 
Net cash flows from financing activities -81350000 -
110886000 
-94412000 576575000 347218000 
Net increase (decrease) in cash & cash equivalents -15935000 9175000 16625000 -387584000 243994000 
Cash & cash equivalents at beginning of year 12688400
0 
117709000 101084000 488668000 244674000 
Cash & cash equivalents at end of year 11094900
0 
126884000 117709000 101084000 488668000 
Cash paid (received) during the period for taxes, net of refunds 6472000 121000 -14425000 -4048000 58318000 
Cash paid during the period for interest 48440000 55542000 71093000 39511000 - 
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FinSAS Version 2003051213 Ratios - average 
   
Company: ANI 
    
Analyst: Julia 
    
Most Recent Year Available: 2018  
    
Years Available for: 
     
   Income Statement (1-5)          5  
    
   Balance Sheet    (1-5)          5  
    
      
      
- - - - - - 
LIQUIDITY 2018  2017  2016  2015  2014  
- - - - - - 
Days' Sales in Receivables 203.79  192.93  219.73  169.86  169.59  
Accounts Receivable Turnover 1.96  2.07  2.28  2.48  4.30  
A/R Turnover in Days 186.52  176.37  160.26  147.11  #N/A 
      
Days' Sales in Inventory 202.45  174.24  195.92  384.99  239.18  
Inventory Turnover 1.87  2.47  2.47  1.21  3.05  
Inventory Turnover in Days 195.51  147.58  148.04  300.60  #N/A 
      
Operating Cycle 382.04  323.95  308.30  447.71  #N/A 
Working Capital ########### ########### ########### ########### ########### 
Current Ratio 0.92  3.35  3.22  16.38  15.38  
      
Acid Test 0.65  2.29  2.29  15.02  14.08  
Cash Ratio 0.26  0.79  0.86  13.16  12.77  
Sales to Working Capital 5.06  2.16  1.02  0.41  0.59  
      
Cash Flow/Cur. Mat. of Debt & NP #VALUE! #DIV/0! #DIV/0! #DIV/0! #DIV/0! 
      
- - - - - - 
LONG-TERM DEBT-PAYING ABILITY 2018  2017  2016  2015  2014  
- - - - - - 
Times Interest Earned 2.36  2.36  1.77  2.97  25.62  
Fixed Charge Coverage 2.36  2.36  1.77  2.97  25.62  
Debt Ratio 54.19% 57.60% 47.46% 43.88% 46.99% 
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Debt/Equity 118.29% 135.84% 90.31% 78.20% 88.65% 
Debt to Tangible Net Worth -5375.28% -431.34% -2493.75% 133.62% 126.82% 
Cash Flow/Total Debt #VALUE! 0.00% 0.00% 0.00% 0.00% 
      
- - - - - - 
PROFITABILITY 2018  2017  2016  2015  2014  
- - - - - - 
Net Profit Margin 7.69% #N/A 3.06% 20.14% 51.36% 
Total Asset Turnover 0.48  0.48  0.42  0.28  0.42  
Return on Assets 3.68% #N/A 1.29% 5.60% 21.80% 
      
Operating Income Margin 17.54% 16.02% 15.61% 42.84% 35.74% 
Operating Asset Turnover 1.03  1.14  0.72  0.35  0.51  
Return on Operating Assets 18.12% 18.23% 11.29% 15.06% 18.24% 
      
Sales to Fixed Assets 9.42  21.51  22.09  15.67  23.34  
Return on Investment 9.48% 3.30% 5.41% 10.07% 23.58% 
Return on Total Equity 8.33% #N/A 2.39% 10.25% 41.13% 
      
Return on Common Equity 8.33% #N/A 2.39% 10.25% 41.13% 
Gross Profit Margin 63.77% 55.31% 62.07% 83.37% 79.50% 
      
- - - - - - 
INVESTOR ANALYSIS 2018  2017  2016  2015  2014  
- - - - - - 
Degree of Financial Leverage 1.74  1.74  2.31  1.51  1.04  
Earnings per Share 0.00  0.00  0.00  0.00  0.00  
Price/Earnings Ratio #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! 
      
Percentage of Earnings Retained 100.00% #N/A 100.00% 100.00% 100.00% 
Dividend Payout #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! 
Dividend Yield #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! 
      
Book Value per Share #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! 
Materiality of Options #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! 
Oper. Cash Flow per Share #VALUE! #DIV/0! #DIV/0! #DIV/0! #DIV/0! 
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Oper. Cash Flow/Cash Dividends #VALUE! #DIV/0! #DIV/0! #DIV/0! #DIV/0! 
Year-end Market Price 0.00  0.00  0.00  0.00  0.00  
= = = = = = 
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FinSAS Version 2003051213 Ratios - average 
   
Company: Assertio 
    
Analyst: Julia 
    
Most Recent Year Available: 2018  
    
Years Available for: 
     
   Income Statement (1-5)          5  
    
   Balance Sheet    (1-5)          5  
    
      
      
- - - - - - 
LIQUIDITY 2018  2017  2016  2015  2014  
- - - - - - 
Days' Sales in Receivables 104.50  69.64  82.28  76.56  89.73  
Accounts Receivable Turnover 2.37  4.34  5.22  6.85  8.14  
A/R Turnover in Days 154.03  84.11  69.89  53.28  #N/A 
      
Days' Sales in Inventory 67.09  65.57  54.42  56.41  203.78  
Inventory Turnover 2.25  5.57  7.43  7.17  3.58  
Inventory Turnover in Days 162.37  65.55  49.12  50.93  #N/A 
      
Operating Cycle 316.40  149.66  119.01  104.21  #N/A 
Working Capital ##########
# 
########### ##########
# 
##########
# 
##########
# 
Current Ratio 0.85  0.74  1.35  1.41  10.74  
      
Acid Test 0.60  0.65  1.23  1.28  10.22  
Cash Ratio 0.45  0.41  0.78  0.96  9.73  
Sales to Working Capital -2.21  -990.56  5.41  1.05  0.41  
      
Cash Flow/Cur. Mat. of Debt & NP #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! 
      
- - - - - - 
LONG-TERM DEBT-PAYING ABILITY 2018  2017  2016  2015  2014  
- - - - - - 
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Times Interest Earned 1.55  #N/A 0.23  #N/A 23.98  
Fixed Charge Coverage 1.55  #N/A 0.23  #N/A 23.98  
Debt Ratio 76.38% 83.68% 79.53% 76.89% 48.75% 
      
Debt/Equity 323.39% 512.72% 388.59% 332.76% 95.11% 
Debt to Tangible Net Worth -151.04% -139.20% -149.62% -151.08% 118.67% 
Cash Flow/Total Debt 0.00% 0.00% 0.00% 0.00% 0.00% 
      
- - - - - - 
PROFITABILITY 2018  2017  2016  2015  2014  
- - - - - - 
Net Profit Margin 28.40% #N/A #N/A #N/A 115.36% 
Total Asset Turnover 0.13  0.34  0.35  0.33  0.32  
Return on Assets 3.74% #N/A #N/A #N/A 37.06% 
      
Operating Income Margin 33.59% #N/A 5.39% #N/A 207.33% 
Operating Asset Turnover 0.55  1.34  1.39  0.70  0.36  
Return on Operating Assets 18.43% #N/A 7.49% #N/A 74.15% 
      
Sales to Fixed Assets 9.96  26.61  30.02  31.28  32.38  
Return on Investment 14.95% #N/A #N/A #N/A 43.16% 
Return on Total Equity 18.93% #N/A #N/A #N/A 72.31% 
      
Return on Common Equity 18.93% #N/A #N/A #N/A 72.31% 
Gross Profit Margin 85.78% 80.89% 80.79% 80.13% 86.74% 
      
- - - - - - 
INVESTOR ANALYSIS 2018  2017  2016  2015  2014  
- - - - - - 
Degree of Financial Leverage 2.81  #N/A #N/A #N/A 1.04  
Earnings per Share 0.00  0.00  0.00  0.00  0.00  
Price/Earnings Ratio #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! 
      
Percentage of Earnings Retained 100.00% #N/A #N/A #N/A 100.00% 
Dividend Payout #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! 
Dividend Yield #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! 
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Book Value per Share #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! 
Materiality of Options #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! 
Oper. Cash Flow per Share #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! 
      
Oper. Cash Flow/Cash Dividends #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! 
Year-end Market Price 0.00  0.00  0.00  0.00  0.00  
= = = = = = 
 
 
 
 
 
 
 
APPENDIX C: VALUATION 
 
 
Projections and Valuation        
Estimated price for most recent fiscal year 12/31/2018 = 
 $        
33.47      
Estimated price for target date 3/31/2020 = 
 $        
41.17      
  
Most 
Recent Projected Projected Projected Projected Projected 
  12/31/18 12/31/19 12/31/20 12/31/21 12/31/22 12/31/23 
Income Statement ($ Thousands)       
Sales  
 $ 
201,576,000  
 $ 
229,769,420  
 $   
239,193,398  
 $   
246,633,352  
 $   
254,059,659  
 $   
261,684,269  
Costs of goods sold (COGS)  
      
73,024,000  
      
83,237,499  
        
82,608,876  
        
81,406,694  
        
80,342,394  
        
79,477,125  
Sales, general and administrative expense (SGA) 
      
60,001,000  
      
68,393,038  
        
64,440,676  
        
60,140,438  
        
56,074,881  
        
52,280,961  
Depreciation  
      
33,742,000  
      
38,461,324  
        
38,774,226  
        
38,800,436  
        
38,869,040  
        
39,010,626  
Operating profit  
 $   
34,809,000  
 $   
39,677,560  
 $     
53,369,621  
 $     
66,285,782  
 $     
78,773,344  
 $     
90,915,558  
Interest expense  
      
14,758,000  
        
3,617,160  
        
29,902,027  
        
35,462,974  
        
40,489,221  
        
39,270,135  
Interest income  
                    
0  
                    
0  
         
8,644,416  
        
13,240,201  
        
16,245,674  
        
19,231,464  
Nonoperating income (Expense)  
                    
0  
                    
0  
                      
0  
                      
0  
                      
0  
                      
0  
Earnings before taxes (EBT)  
 $   
20,051,000  
 $   
36,060,400  
 $     
32,112,010  
 $     
44,063,010  
 $     
54,529,797  
 $     
70,876,886  
Tax expense  
        
4,557,000  
        
7,572,684  
         
6,743,522  
         
9,253,232  
        
11,451,257  
        
14,884,146  
Net income before extraordinary items  
 $   
15,494,000  
 $   
28,487,716  
 $     
25,368,488  
 $     
34,809,778  
 $     
43,078,540  
 $     
55,992,740  
After-tax extraordinary income (Expense)  
                    
0  
                    
0  
                      
0  
                      
0  
                      
0  
                      
0  
Net income (NI)   
 $   
15,494,000  
 $   
28,487,716  
 $     
25,368,488  
 $     
34,809,778  
 $     
43,078,540  
 $     
55,992,740  
        
Dividends-- preferred  
 $                 
0  
 $                 
0  
 $                   
0  
 $                   
0  
 $                   
0  
 $                   
0  
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Dividends-- common  
 $                 
0  
 $                 
0  
 $                   
0  
 $                   
0  
 $                   
0  
 $                   
0  
Additions to RE  
 $   
15,494,000  
 $   
28,487,716  
 $     
25,368,488  
 $     
34,809,778  
 $     
43,078,540  
 $     
55,992,740  
        
Balance Sheets ($ Thousands) 12/31/18 12/31/19 12/31/20 12/31/21 12/31/22 12/31/23 
Assets        
Cash  
 $   
43,008,000  
 $   
49,023,312  
 $     
51,034,000  
 $     
52,621,379  
 $     
54,205,847  
 $     
55,832,624  
Inventory  
      
40,503,000  
      
46,167,951  
        
48,061,526  
        
49,556,448  
        
51,048,629  
        
52,580,654  
Accounts receivable  
      
64,842,000  
      
73,911,124  
        
76,942,584  
        
79,335,833  
        
81,724,692  
        
84,177,340  
Other short-term operating assets  
        
4,524,000  
        
5,156,749  
         
5,368,253  
         
5,535,229  
         
5,701,899  
         
5,873,019  
Short-term investments  
                    
0  
    
465,500,257  
      
560,781,732  
      
576,686,441  
      
595,452,935  
      
622,892,263  
Total current assets  
 $ 
152,877,000  
 $ 
639,759,393  
 $   
742,188,095  
 $   
763,735,330  
 $   
788,134,000  
 $   
821,355,900  
Net plant, property, & equipment (PPE)  
      
38,090,000  
      
43,417,456  
        
45,198,221  
        
46,604,082  
        
48,007,364  
        
49,448,118  
Other long-term operating assets  
    
239,637,000  
    
273,153,820  
      
284,357,206  
      
293,201,951  
      
302,030,473  
      
311,094,740  
Long-term investments  
                    
0  
                    
0  
                      
0  
                      
0  
                      
0  
                      
0  
Total Assets  
 $ 
430,604,000  
 $ 
956,330,670  
 
$1,071,743,5
22  
 
$1,103,541,3
63  
 
$1,138,171,8
37  
 
$1,181,898,7
58  
        
Liabilities and Equity        
Accounts payable (AP)  
 $     
8,884,000  
 $   
10,126,560  
 $     
10,541,901  
 $     
10,869,799  
 $     
11,197,097  
 $     
11,533,134  
Accruals  
                    
0  
                    
0  
                      
0  
                      
0  
                      
0  
                      
0  
Other operating current liabilities  
    
156,665,000  
    
178,576,945  
      
185,901,266  
      
191,683,603  
      
197,455,335  
      
203,381,187  
All short-term debt  
                    
0  
                    
0  
        
89,932,745  
        
97,365,562  
      
104,384,996  
      
111,014,338  
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Total current liabilities  
 $ 
165,549,000  
 $ 
188,703,505  
 $   
286,375,911  
 $   
299,918,965  
 $   
313,037,428  
 $   
325,928,659  
Long-term debt  
      
67,296,000  
    
541,311,076  
      
533,659,846  
      
517,086,548  
      
495,501,747  
      
470,325,935  
Deferred taxes  
                    
0  
                    
0  
                      
0  
                      
0  
                      
0  
                      
0  
Preferred stock  
                    
0  
                    
0  
                      
0  
                      
0  
                      
0  
                      
0  
Other long-term liabilities  
          
496,000  
          
565,373  
            
588,562  
            
606,869  
            
625,142  
            
643,903  
Total liabilities  
 $ 
233,341,000  
 $ 
730,579,954  
 $   
820,624,319  
 $   
817,612,381  
 $   
809,164,316  
 $   
796,898,496  
Par plus PIC Less treasury (and other adjustments) 
    
134,789,000  
    
134,789,000  
      
134,789,000  
      
134,789,000  
      
134,789,000  
      
134,789,000  
Retained earnings (RE)  
      
62,474,000  
      
90,961,716  
      
116,330,203  
      
151,139,981  
      
194,218,521  
      
250,211,261  
Total common equity  
 $ 
197,263,000  
 $ 
225,750,716  
 $   
251,119,203  
 $   
285,928,981  
 $   
329,007,521  
 $   
385,000,261  
Total liabilities and equity  
 $ 
430,604,000  
 $ 
956,330,670  
 
$1,071,743,5
22  
 
$1,103,541,3
63  
 
$1,138,171,8
37  
 
$1,181,898,7
58  
        
                
Info for making the sheets balance       
Specified assets   490,830,413  510,961,790  526,854,922  542,718,903  559,006,495  
Specified liabilities   956,330,670  
1,071,743,52
2  
1,103,541,36
3  
1,138,171,83
7  
1,181,898,75
8  
Net required financing   
(465,500,25
7) (560,781,732) (576,686,441) (595,452,935) (622,892,263) 
        
Current debt   0  0  0  0  0  
Short-term investments   465,500,257  560,781,732  576,686,441  595,452,935  622,892,263  
Balance check: TA-TL    Balance   Balance   Balance   Balance   Balance  
                
Valuation        
        
Calculating Projected FCF        
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Marginal tax rate  22.7% 21.0% 21.0% 21.0% 21.0% 21.0% 
Reported income tax expense  4,557,000  7,572,684  6,743,522  9,253,232  11,451,257  14,884,146  
Taxes reported but not paid  0  0  0  0  0  0  
Actual taxes paid  4,557,000  7,572,684  6,743,522  9,253,232  11,451,257  14,884,146  
Plus tax saved due to net interest expenses  3,354,057  759,604  4,464,098  4,666,782  5,091,145  4,208,121  
Minus tax paid on non-operating income  0  0  0  0  0  0  
Tax on operating income  7,911,057  8,332,288  11,207,620  13,920,014  16,542,402  19,092,267  
Net operating profit after taxes (NOPAT)  26,897,943  31,345,272  42,162,000  52,365,768  62,230,942  71,823,290  
NOPAT adjusted for extraordinary income  26,897,943  31,345,272  42,162,000  52,365,768  62,230,942  71,823,290  
Operating current assets  152,877,000  174,259,136  181,406,363  187,048,889  192,681,066  198,463,637  
Operating current liabilities  165,549,000  188,703,505  196,443,167  202,553,403  208,652,432  214,914,321  
Net operating working capital  (12,672,000) (14,444,369) (15,036,804) (15,504,514) (15,971,366) (16,450,684) 
Operating long term capital  277,727,000  316,571,277  329,555,427  339,806,033  350,037,837  360,542,858  
Operating capital (adjusted for any special asset impairment of 
accounting changes) 265,055,000  302,126,908  314,518,623  324,301,519  334,066,471  344,092,174  
Investment in operating capital  
(107,855,00
0) 37,071,908  12,391,715  9,782,896  9,764,952  10,025,703  
Free cash flow (including extraordinary income)  134,752,943  (5,726,636) 29,770,285  42,582,873  52,465,989  61,797,588  
        
Calculating Projected ROIC        
ROIC (NOPAT/ Beginning capital)  7.2% 11.8% 14.0% 16.6% 19.2% 21.5% 
        
Projected Growth Rates        
Growth in Sales   14.0% 4.1% 3.1% 3.0% 3.0% 
Growth in NOPAT   16.5% 34.5% 24.2% 18.8% 15.4% 
Growth in operating capital   14.0% 4.1% 3.1% 3.0% 3.0% 
Growth in FCF   -104.2% -619.9% 43.0% 23.2% 17.8% 
        
Calculating Value        
WACC  15.91% 15.91% 15.91% 15.91% 15.91% 15.91% 
Assumed long-term return on invested capital        
Horizon value        
Value of operations  431,703,647  506,120,895  556,882,138  602,907,678  646,373,464  687,423,719  
Value of operations adjusted for half-year convention  464,781,698  544,900,954  599,551,630  649,103,745  695,899,973  740,095,585  
Value of investments  0  465,500,257  560,781,732  576,686,441  595,452,935  622,892,263  
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Total value of firm  464,781,698  
1,010,401,21
1  
1,160,333,36
3  
1,225,790,18
6  
1,291,352,90
7  
1,362,987,84
9  
Value of all debt, preferred stock, and other 
nonoperating liabilities  67,792,000  541,876,449  624,181,152  615,058,979  600,511,885  581,984,176  
Value of equity  396,989,698  468,524,761  536,152,211  610,731,208  690,841,022  781,003,673  
Number of shares  11,862,193  11,862,193  11,862,193  11,862,193  11,862,193  11,862,193  
Estimated price per share, end of fiscal year 
 $        
33.47  
 $        
39.50  
 $          
45.20  
 $          
51.49  
 $          
58.24  
 $          
65.84  
        
Price per share on target date       
Most recent actual fiscal year end 12/31/2018       
Target valuation date 3/31/2020       
Most recent fiscal year-end prior to target date 12/31/2018       
Number of days from target to fiscal year-end prior to 
target 456.00       
Value of operations on target date 
566,940,39
0        
Value of investments on target date 
581,556,48
5        
Total value of firm on target date 
1,148,496,8
75        
Value of debt, preferred stock, and other nonoperating 
liabilities on target date 
660,072,84
6        
Value of equity on target date 
488,424,02
9        
Number of shares on target date 11,862,193        
Price per share, target date 
 $       
41.17        
        
Selected Projected Ratios and Other Data      
Projected economic profit (EP)  26,897,942  (10,829,007) (5,910,983) 2,321,075  10,629,641  18,668,237  
Projected market value added (MVA)  199,726,698  242,774,046  285,033,007  324,802,226  361,833,501  396,003,412  
Price/earnings ratio (P/E ratio)  25.6 16.4 21.1 17.5 16.0 13.9 
Market to book ratio  2.0 2.1 2.1 2.1 2.1 2.0 
Value/EBITDA ratio  6.8 12.9 12.6 11.7 11.0 10.5 
Value/Sales ratio  2.3 4.4 4.9 5.0 5.1 5.2 
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Times-interest-earned ratio  2.4 11.0 2.5 3.0 3.2 4.5 
Long-term debt/value of operations   99.3% 89.0% 79.7% 71.2% 63.5% 
        
Statement of Cash Flows        
Operating Activities        
Net income 
 
 $   
15,494,000  
 $   
28,487,716  
 $     
25,368,488  
 $     
34,809,778  
 $     
43,078,540  
 $     
55,992,740  
Depreciation 
 
      
33,742,000  
      
38,461,324  
        
38,774,226  
        
38,800,436  
        
38,869,040  
        
39,010,626  
Change in deferred tax 
 
                    
0  
                    
0  
                      
0  
                      
0  
                      
0  
                      
0   
 
      
Change in inventory 
 
       
(2,776,000) 
       
(5,664,951) 
        
(1,893,575) 
        
(1,494,922) 
        
(1,492,180) 
        
(1,532,026) 
Change in accounts receivable 
 
       
(6,054,000) 
       
(9,069,124) 
        
(3,031,460) 
        
(2,393,249) 
        
(2,388,859) 
        
(2,452,648) 
Change in other short-term operating assets 
 
         
(578,000) 
         
(632,749) 
           
(211,504) 
           
(166,976) 
           
(166,670) 
           
(171,120) 
Change in accounts payable 
 
        
5,254,000  
        
1,242,560  
            
415,340  
            
327,899  
            
327,297  
            
336,037  
Change in accruals 
 
                    
0  
                    
0  
                      
0  
                      
0  
                      
0  
                      
0  
Change in other current liabilities 
 
    
121,067,000  
      
21,911,945  
         
7,324,322  
         
5,782,337  
         
5,771,731  
         
5,925,852  
Net cash from operating activities 
 
 $ 
166,149,000  
 $   
74,736,720  
 $     
66,745,836  
 $     
75,665,303  
 $     
83,998,900  
 $     
97,109,462  
        
Investing Activities        
Investment in PPE 
 
 $  
(51,429,000) 
 $  
(43,788,780) 
 $    
(40,554,990) 
 $    
(40,206,297) 
 $    
(40,272,323) 
 $    
(40,451,380) 
Investment in other long-term oper. ass. 
 
      
20,493,000  
     
(33,516,820) 
       
(11,203,386) 
        
(8,844,745) 
        
(8,828,522) 
        
(9,064,267) 
Net cash from investing activities 
 
 $  
(30,936,000) 
 $  
(77,305,601) 
 $    
(51,758,376) 
 $    
(49,051,042) 
 $    
(49,100,845) 
 $    
(49,515,647) 
        
Financing Activities        
Change in short-term investments 
 
 $                 
0  
 
$(465,500,2
57) 
 $    
(95,281,475) 
 $    
(15,904,709) 
 $    
(18,766,494) 
 $    
(27,439,329) 
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Change in long-term investments 
 
                    
0  
                    
0  
                      
0  
                      
0  
                      
0  
                      
0  
Change in short-term debt 
 
                    
0  
                    
0  
        
89,932,745  
         
7,432,817  
         
7,019,434  
         
6,629,342  
Change in long-term debt 
 
       
(2,650,000) 
    
474,015,076  
        
(7,651,231) 
       
(16,573,298) 
       
(21,584,801) 
       
(25,175,812) 
Preferred dividends 
 
                    
0  
                    
0  
                      
0  
                      
0  
                      
0  
                      
0  
Change in preferred stock 
 
                    
0  
                    
0  
                      
0  
                      
0  
                      
0  
                      
0  
Change in other long-term liabilities 
 
   
(127,712,00
0) 
            
69,373  
              
23,189  
              
18,307  
              
18,273  
              
18,761  
Change in common stock (Par + PIC) 
 
        
7,013,000  
                    
0  
                      
0  
                      
0  
                      
0  
                      
0  
Common dividends 
 
                    
0  
                    
0  
                      
0  
                      
0  
                      
0  
                      
0  
         Net cash from financing activities 
 
 
$(123,349,0
00) 
 $     
8,584,192  
 $    
(12,976,773) 
 $    
(25,026,882) 
 $    
(33,313,587) 
 $    
(45,967,038) 
        
Net cash flow 
 
 $   
11,864,000  
 $     
6,015,312  
 $       
2,010,688  
 $       
1,587,379  
 $       
1,584,468  
 $       
1,626,777  
Starting cash 
 
      
31,144,000  
      
43,008,000  
        
49,023,312  
        
51,034,000  
        
52,621,379  
        
54,205,847  
Ending cash 
 
 $   
43,008,000  
 $   
49,023,312  
 $     
51,034,000  
 $     
52,621,379  
 $     
54,205,847  
 $     
55,832,624  
 
  
